athenahealth, Inc. ATHN
Elliott's $160 cash offer for athenahealth is being stonewalled by a disengaged board; immediate engagement on a take-private transaction is the value-maximizing path for shareholders.
Thesis
Elliott disclosed a $160-per-share cash proposal to acquire athenahealth and signaled it could raise the bid with diligence access, but the board has ignored Elliott's follow-up communications and, Elliott claims, other interested acquirers as well. Elliott notes this mirrors the board's refusal to engage on a prior November approach, when athenahealth neither hired an investment bank nor substantively responded, dismissing Elliott's interest in an unsigned one-paragraph letter. Elliott argues this pattern of non-engagement disserves shareholders and cites shareholders, analysts, and media voices urging the board to negotiate. The letter demands that athenahealth's board immediately open confirmatory diligence and begin working toward a definitive take-private agreement with Elliott, which has a full deal team standing by. Though short, the letter functions as public pressure meant to shame directors into engaging.
SCQA
athenahealth is a publicly traded healthcare-IT company that Elliott believes is a strong take-private candidate, having previously approached the board in November 2017 and publicly disclosed a $160-per-share cash acquisition proposal the prior week.
The board has stonewalled Elliott — ignoring emails, declining to hire an advisor, and dismissing interest in a careless unsigned letter — and appears to have rebuffed other would-be acquirers, disadvantaging shareholders by refusing to run any genuine process.
Elliott demands that athenahealth's directors immediately open confirmatory diligence and negotiate toward a definitive take-private transaction at $160 per share or a higher price Elliott says it could offer with diligence access.
Shareholders capture an immediate all-cash $160 floor — with potential upside if diligence supports a raise — versus leaving value on the table under a board that has repeatedly refused to test the market.
The three reasons
- 1
Board has ignored Elliott's $160/share cash offer and prior November approach entirely.
- 2
Company engaged no investment bank; dismissed Elliott with an unsigned one-paragraph reply.
- 3
Other interested acquirers also rebuffed, depriving shareholders of a genuine sale process.
Primary demands
- Immediately engage with Elliott on its $160/share cash acquisition proposal
- Open confirmatory diligence so Elliott can consider raising its offer
- Run a genuine sale process and engage with all serious potential acquirers
- Hire qualified financial advisors to evaluate take-private interest
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Notable slides (1)
Notes
Short two-page public pressure letter from Jesse Cohn (Elliott) to athenahealth's board, following Elliott's public $160/share take-private proposal the prior week and a rebuffed November 2017 approach. Letter catalogs specific grievances — ignored emails, no advisor hired, unsigned one-paragraph dismissal, other acquirers also stonewalled — and is useful as a specimen of activist public-shaming rhetoric rather than a full thesis deck. No stake, no valuation work, no charts. Campaign ultimately won: Veritas/Evergreen Coast Capital (Elliott) took athenahealth private in February 2019 at $135/share, though this particular letter precedes that outcome.